Skip to main content
    I

    ImmuCell Corporation (ICCC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.42
    +0.67 (+6.23%)

    Market Cap: $97.73M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ImmuCell Corporation (ICCC) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    ImmuCell (ICCC) trades at 57.2x trailing earnings and 3.1x sales. Its P/S of 3.1x is above its 5-year median of 2.3x.

    Current Multiples

    Its enterprise value is 25.3x its EBITDA. Its free cash flow yield is 5.2%.

    MultipleValue
    P/E (trailing)57.2x
    Forward P/EN/A
    Price to sales3.1x
    Price to book3.2x
    EV/EBITDA25.3x
    Price to FCF19.2x
    EV/FCF19.2x
    PEGN/A
    FCF yield5.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 19.2% above 2.6x and its P/B is 100.0% above 1.6x.

    MultipleCurrent5-year median10-year median
    P/S3.1x2.3x2.6x
    P/B3.2x1.7x1.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.6x in 2024 to 4.2x in 2017.

    Year endPriceP/EP/SP/B
    2025$6.15N/A2.0x2.1x
    2024$5.15N/A1.6x1.7x
    2023$5.09N/A2.3x1.5x
    2022$6.10N/A2.5x1.6x
    2021$8.00N/A3.2x1.9x
    2020$5.95N/A2.8x1.5x
    2019$5.15N/A2.3x1.0x
    2018$7.05N/A3.5x1.8x
    2017$8.79N/A4.2x1.9x
    2016$5.9546.9x2.6x1.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ICCC

    Is ICCC stock overvalued?

    GNG's valuation label for ICCC is Fairly valued.

    What is ICCC's price to sales ratio?

    ImmuCell has a price to sales ratio of 3.1x.